polatuzumab vedotin,prednisone,vedolizumab,cyclophosphamide,rituximab,vincristine,doxorubicin
roche,takeda
['vincristine', 'pola', 'prednisone', 'dlbcl', 'ritux', 'doxorubicin', ' vedo', 'rituximab', 'polatuzumab', 'cyclophosphamide']
researchers explored efficacy and safety of polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in elderly patients with #dlbcl #asco23 
Reporting essential clinical news w/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology/hematology